Breyanzi (lisocabtagene maraleucel) - BMS
MB-106 - Fortress
ibrutinib - Generic mfg.
Rituxan (rituximab) - Biogen, Zenyaku Kogyo, Roche
Tab-cel (tabelecleucel) - Atara
bortezomib - Generic mfg.
Ninlaro (ixazomib) - Takeda
Yescarta (axicabtagene ciloleucel) - Gilead, Daiichi Sankyo
Keytruda (pembrolizumab) - Merck (MSD)
IGM-2323 - IGM Biosciences
Brukinsa (zanubrutinib) - BeiGene, Medison
Adcetris (brentuximab vedotin) - Seagen, Takeda
axatilamab (SNDX-6352) - Syndax Pharma
tranexamic acid (LB1148) - Palisade Bio
Tasigna (nilotinib) - Novartis, Inhibikase
parsaclisib (INCB50465) - Incyte
crenolanib besylate (ARO-002) - AROG
https://www.businesswire.com/news/home/20201204005415/en/Seattle-Cancer-Care-Alliance-to-Present-New-Research-at-62nd-Annual-Meeting-of-the-American-Society-of-Hematology
 
Dec 4, 2020
 
Prev Next